Indy Hematology Review
D

2024 Updates on Understanding & Managing Immune Effector Cell Toxicities in Hematologic Malignancies

By Indy Hematology Review FEATURING David Reeves
By Indy Hematology Review FEATURING David Reeves
0 views
April 30, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Recommended

AUTOPLAY
17:52
Indy Hematology Review

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Feat. K. Anderson
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
13:07
Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez
07:11
GRACE

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

Feat. A. Goodman, A. Jeong, S. Rajeeve
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
24:23
MyCancerHaven

Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?

Feat. R. Vij, S. Al Hadidi
24:35
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 …

Feat. H. Hashmi
05:35
Saurabh Chhabra

Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence

35:27
Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

09:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…

Feat. J. Westin
20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

Feat. R. Gale
36:10
Insights from 2024 EHA Annual Meeting

Highlights in Plasma Cell Disorders From ASCO® and EHA

Feat. S. Al Hadidi
12:38
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

Feat. S. Usmani
26:46
Samer Al Hadidi

CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…

14:09
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…

Feat. H. Hashmi
03:42
Moffitt Cancer Center

Multiple Myeloma: What You Need to Know About New FDA Approvals of C…

Feat. D. Hansen
08:23
Total Health

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Feat. J. Chandler, B. Randolph, M. Onciu